What Differentiates Abemaciclib, Ribociclib, and Palbociclib?

Videos — January 10, 2018

Featuring:

Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer.

Related Articles